1 Study Coverage
    1.1 Human Vaccines Administered Orally Product Introduction
    1.2 Market by Type
        1.2.1 Global Human Vaccines Administered Orally Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Rotavirus Vaccine
        1.2.3 Cholera Vaccine
        1.2.4 Oral Polio Vaccine
    1.3 Market by Application
        1.3.1 Global Human Vaccines Administered Orally Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Public
        1.3.3 Private
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Human Vaccines Administered Orally Sales Estimates and Forecasts 2017-2028
    2.2 Global Human Vaccines Administered Orally Revenue Estimates and Forecasts 2017-2028
    2.3 Global Human Vaccines Administered Orally Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Human Vaccines Administered Orally Sales by Region
        2.4.1 Global Human Vaccines Administered Orally Sales by Region (2017-2022)
        2.4.2 Global Sales Human Vaccines Administered Orally by Region (2023-2028)
    2.5 Global Human Vaccines Administered Orally Revenue by Region
        2.5.1 Global Human Vaccines Administered Orally Revenue by Region (2017-2022)
        2.5.2 Global Human Vaccines Administered Orally Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Human Vaccines Administered Orally Sales by Manufacturers
        3.1.1 Global Top Human Vaccines Administered Orally Manufacturers by Sales (2017-2022)
        3.1.2 Global Human Vaccines Administered Orally Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Human Vaccines Administered Orally in 2021
    3.2 Global Human Vaccines Administered Orally Revenue by Manufacturers
        3.2.1 Global Human Vaccines Administered Orally Revenue by Manufacturers (2017-2022)
        3.2.2 Global Human Vaccines Administered Orally Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Human Vaccines Administered Orally Revenue in 2021
    3.3 Global Human Vaccines Administered Orally Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Human Vaccines Administered Orally Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Human Vaccines Administered Orally Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Human Vaccines Administered Orally Sales by Type
        4.1.1 Global Human Vaccines Administered Orally Historical Sales by Type (2017-2022)
        4.1.2 Global Human Vaccines Administered Orally Forecasted Sales by Type (2023-2028)
        4.1.3 Global Human Vaccines Administered Orally Sales Market Share by Type (2017-2028)
    4.2 Global Human Vaccines Administered Orally Revenue by Type
        4.2.1 Global Human Vaccines Administered Orally Historical Revenue by Type (2017-2022)
        4.2.2 Global Human Vaccines Administered Orally Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Human Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
    4.3 Global Human Vaccines Administered Orally Price by Type
        4.3.1 Global Human Vaccines Administered Orally Price by Type (2017-2022)
        4.3.2 Global Human Vaccines Administered Orally Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Human Vaccines Administered Orally Sales by Application
        5.1.1 Global Human Vaccines Administered Orally Historical Sales by Application (2017-2022)
        5.1.2 Global Human Vaccines Administered Orally Forecasted Sales by Application (2023-2028)
        5.1.3 Global Human Vaccines Administered Orally Sales Market Share by Application (2017-2028)
    5.2 Global Human Vaccines Administered Orally Revenue by Application
        5.2.1 Global Human Vaccines Administered Orally Historical Revenue by Application (2017-2022)
        5.2.2 Global Human Vaccines Administered Orally Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Human Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
    5.3 Global Human Vaccines Administered Orally Price by Application
        5.3.1 Global Human Vaccines Administered Orally Price by Application (2017-2022)
        5.3.2 Global Human Vaccines Administered Orally Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Human Vaccines Administered Orally Market Size by Type
        6.1.1 North America Human Vaccines Administered Orally Sales by Type (2017-2028)
        6.1.2 North America Human Vaccines Administered Orally Revenue by Type (2017-2028)
    6.2 North America Human Vaccines Administered Orally Market Size by Application
        6.2.1 North America Human Vaccines Administered Orally Sales by Application (2017-2028)
        6.2.2 North America Human Vaccines Administered Orally Revenue by Application (2017-2028)
    6.3 North America Human Vaccines Administered Orally Market Size by Country
        6.3.1 North America Human Vaccines Administered Orally Sales by Country (2017-2028)
        6.3.2 North America Human Vaccines Administered Orally Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Human Vaccines Administered Orally Market Size by Type
        7.1.1 Europe Human Vaccines Administered Orally Sales by Type (2017-2028)
        7.1.2 Europe Human Vaccines Administered Orally Revenue by Type (2017-2028)
    7.2 Europe Human Vaccines Administered Orally Market Size by Application
        7.2.1 Europe Human Vaccines Administered Orally Sales by Application (2017-2028)
        7.2.2 Europe Human Vaccines Administered Orally Revenue by Application (2017-2028)
    7.3 Europe Human Vaccines Administered Orally Market Size by Country
        7.3.1 Europe Human Vaccines Administered Orally Sales by Country (2017-2028)
        7.3.2 Europe Human Vaccines Administered Orally Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Human Vaccines Administered Orally Market Size by Type
        8.1.1 Asia Pacific Human Vaccines Administered Orally Sales by Type (2017-2028)
        8.1.2 Asia Pacific Human Vaccines Administered Orally Revenue by Type (2017-2028)
    8.2 Asia Pacific Human Vaccines Administered Orally Market Size by Application
        8.2.1 Asia Pacific Human Vaccines Administered Orally Sales by Application (2017-2028)
        8.2.2 Asia Pacific Human Vaccines Administered Orally Revenue by Application (2017-2028)
    8.3 Asia Pacific Human Vaccines Administered Orally Market Size by Region
        8.3.1 Asia Pacific Human Vaccines Administered Orally Sales by Region (2017-2028)
        8.3.2 Asia Pacific Human Vaccines Administered Orally Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Human Vaccines Administered Orally Market Size by Type
        9.1.1 Latin America Human Vaccines Administered Orally Sales by Type (2017-2028)
        9.1.2 Latin America Human Vaccines Administered Orally Revenue by Type (2017-2028)
    9.2 Latin America Human Vaccines Administered Orally Market Size by Application
        9.2.1 Latin America Human Vaccines Administered Orally Sales by Application (2017-2028)
        9.2.2 Latin America Human Vaccines Administered Orally Revenue by Application (2017-2028)
    9.3 Latin America Human Vaccines Administered Orally Market Size by Country
        9.3.1 Latin America Human Vaccines Administered Orally Sales by Country (2017-2028)
        9.3.2 Latin America Human Vaccines Administered Orally Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Human Vaccines Administered Orally Market Size by Type
        10.1.1 Middle East and Africa Human Vaccines Administered Orally Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Human Vaccines Administered Orally Revenue by Type (2017-2028)
    10.2 Middle East and Africa Human Vaccines Administered Orally Market Size by Application
        10.2.1 Middle East and Africa Human Vaccines Administered Orally Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Human Vaccines Administered Orally Revenue by Application (2017-2028)
    10.3 Middle East and Africa Human Vaccines Administered Orally Market Size by Country
        10.3.1 Middle East and Africa Human Vaccines Administered Orally Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Human Vaccines Administered Orally Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Merck
        11.1.1 Merck Corporation Information
        11.1.2 Merck Overview
        11.1.3 Merck Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Merck Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Merck Recent Developments
    11.2 GSK
        11.2.1 GSK Corporation Information
        11.2.2 GSK Overview
        11.2.3 GSK Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 GSK Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 GSK Recent Developments
    11.3 Sanofi
        11.3.1 Sanofi Corporation Information
        11.3.2 Sanofi Overview
        11.3.3 Sanofi Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Sanofi Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Sanofi Recent Developments
    11.4 Lanzhou Institute
        11.4.1 Lanzhou Institute Corporation Information
        11.4.2 Lanzhou Institute Overview
        11.4.3 Lanzhou Institute Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Lanzhou Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Lanzhou Institute Recent Developments
    11.5 Serum Institute
        11.5.1 Serum Institute Corporation Information
        11.5.2 Serum Institute Overview
        11.5.3 Serum Institute Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Serum Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Serum Institute Recent Developments
    11.6 Valneva
        11.6.1 Valneva Corporation Information
        11.6.2 Valneva Overview
        11.6.3 Valneva Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Valneva Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Valneva Recent Developments
    11.7 Shanghai United Cell
        11.7.1 Shanghai United Cell Corporation Information
        11.7.2 Shanghai United Cell Overview
        11.7.3 Shanghai United Cell Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Shanghai United Cell Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Shanghai United Cell Recent Developments
    11.8 Bibcol
        11.8.1 Bibcol Corporation Information
        11.8.2 Bibcol Overview
        11.8.3 Bibcol Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Bibcol Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Bibcol Recent Developments
    11.9 PaxVax
        11.9.1 PaxVax Corporation Information
        11.9.2 PaxVax Overview
        11.9.3 PaxVax Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 PaxVax Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 PaxVax Recent Developments
    11.10 Vabiotech
        11.10.1 Vabiotech Corporation Information
        11.10.2 Vabiotech Overview
        11.10.3 Vabiotech Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 Vabiotech Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 Vabiotech Recent Developments
    11.11 Tiantan Biological
        11.11.1 Tiantan Biological Corporation Information
        11.11.2 Tiantan Biological Overview
        11.11.3 Tiantan Biological Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.11.4 Tiantan Biological Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.11.5 Tiantan Biological Recent Developments
    11.12 EuBiologics
        11.12.1 EuBiologics Corporation Information
        11.12.2 EuBiologics Overview
        11.12.3 EuBiologics Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.12.4 EuBiologics Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.12.5 EuBiologics Recent Developments
    11.13 Panacea Biotec Ltd
        11.13.1 Panacea Biotec Ltd Corporation Information
        11.13.2 Panacea Biotec Ltd Overview
        11.13.3 Panacea Biotec Ltd Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.13.4 Panacea Biotec Ltd Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.13.5 Panacea Biotec Ltd Recent Developments
    11.14 Bio-Med
        11.14.1 Bio-Med Corporation Information
        11.14.2 Bio-Med Overview
        11.14.3 Bio-Med Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.14.4 Bio-Med Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.14.5 Bio-Med Recent Developments
    11.15 Halfkin Bio-Pharmaceuticals
        11.15.1 Halfkin Bio-Pharmaceuticals Corporation Information
        11.15.2 Halfkin Bio-Pharmaceuticals Overview
        11.15.3 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2017-2022)
        11.15.4 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
        11.15.5 Halfkin Bio-Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Human Vaccines Administered Orally Industry Chain Analysis
    12.2 Human Vaccines Administered Orally Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Human Vaccines Administered Orally Production Mode & Process
    12.4 Human Vaccines Administered Orally Sales and Marketing
        12.4.1 Human Vaccines Administered Orally Sales Channels
        12.4.2 Human Vaccines Administered Orally Distributors
    12.5 Human Vaccines Administered Orally Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Human Vaccines Administered Orally Industry Trends
    13.2 Human Vaccines Administered Orally Market Drivers
    13.3 Human Vaccines Administered Orally Market Challenges
    13.4 Human Vaccines Administered Orally Market Restraints
14 Key Findings in The Global Human Vaccines Administered Orally Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Human Vaccines Administered Orally Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Rotavirus Vaccine
    Table 3. Major Manufacturers of Cholera Vaccine
    Table 4. Major Manufacturers of Oral Polio Vaccine
    Table 5. Global Human Vaccines Administered Orally Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 6. Global Human Vaccines Administered Orally Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 7. Global Human Vaccines Administered Orally Sales by Region (2017-2022) & (K Units)
    Table 8. Global Human Vaccines Administered Orally Sales Market Share by Region (2017-2022)
    Table 9. Global Human Vaccines Administered Orally Sales by Region (2023-2028) & (K Units)
    Table 10. Global Human Vaccines Administered Orally Sales Market Share by Region (2023-2028)
    Table 11. Global Human Vaccines Administered Orally Revenue by Region (2017-2022) & (US$ Million)
    Table 12. Global Human Vaccines Administered Orally Revenue Market Share by Region (2017-2022)
    Table 13. Global Human Vaccines Administered Orally Revenue by Region (2023-2028) & (US$ Million)
    Table 14. Global Human Vaccines Administered Orally Revenue Market Share by Region (2023-2028)
    Table 15. Global Human Vaccines Administered Orally Sales by Manufacturers (2017-2022) & (K Units)
    Table 16. Global Human Vaccines Administered Orally Sales Share by Manufacturers (2017-2022)
    Table 17. Global Human Vaccines Administered Orally Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 18. Global Human Vaccines Administered Orally Revenue Share by Manufacturers (2017-2022)
    Table 19. Human Vaccines Administered Orally Price by Manufacturers (2017-2022) &(US$/Unit)
    Table 20. Global Human Vaccines Administered Orally Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 21. Global Human Vaccines Administered Orally by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Vaccines Administered Orally as of 2021)
    Table 22. Human Vaccines Administered Orally Manufacturing Base Distribution and Headquarters
    Table 23. Manufacturers Human Vaccines Administered Orally Product Offered
    Table 24. Date of Manufacturers Enter into Human Vaccines Administered Orally Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
    Table 27. Global Human Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
    Table 28. Global Human Vaccines Administered Orally Sales Share by Type (2017-2022)
    Table 29. Global Human Vaccines Administered Orally Sales Share by Type (2023-2028)
    Table 30. Global Human Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
    Table 31. Global Human Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
    Table 32. Global Human Vaccines Administered Orally Revenue Share by Type (2017-2022)
    Table 33. Global Human Vaccines Administered Orally Revenue Share by Type (2023-2028)
    Table 34. Human Vaccines Administered Orally Price by Type (2017-2022) & (US$/Unit)
    Table 35. Global Human Vaccines Administered Orally Price Forecast by Type (2023-2028) & (US$/Unit)
    Table 36. Global Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
    Table 37. Global Human Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
    Table 38. Global Human Vaccines Administered Orally Sales Share by Application (2017-2022)
    Table 39. Global Human Vaccines Administered Orally Sales Share by Application (2023-2028)
    Table 40. Global Human Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
    Table 41. Global Human Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
    Table 42. Global Human Vaccines Administered Orally Revenue Share by Application (2017-2022)
    Table 43. Global Human Vaccines Administered Orally Revenue Share by Application (2023-2028)
    Table 44. Human Vaccines Administered Orally Price by Application (2017-2022) & (US$/Unit)
    Table 45. Global Human Vaccines Administered Orally Price Forecast by Application (2023-2028) & (US$/Unit)
    Table 46. North America Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
    Table 47. North America Human Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
    Table 48. North America Human Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
    Table 49. North America Human Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
    Table 50. North America Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
    Table 51. North America Human Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
    Table 52. North America Human Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
    Table 53. North America Human Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
    Table 54. North America Human Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
    Table 55. North America Human Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
    Table 56. North America Human Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
    Table 57. North America Human Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
    Table 58. Europe Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
    Table 59. Europe Human Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
    Table 60. Europe Human Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
    Table 61. Europe Human Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
    Table 62. Europe Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
    Table 63. Europe Human Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
    Table 64. Europe Human Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
    Table 65. Europe Human Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
    Table 66. Europe Human Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
    Table 67. Europe Human Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
    Table 68. Europe Human Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
    Table 69. Europe Human Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
    Table 70. Asia Pacific Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
    Table 71. Asia Pacific Human Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
    Table 72. Asia Pacific Human Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
    Table 73. Asia Pacific Human Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
    Table 74. Asia Pacific Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
    Table 75. Asia Pacific Human Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
    Table 76. Asia Pacific Human Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
    Table 77. Asia Pacific Human Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
    Table 78. Asia Pacific Human Vaccines Administered Orally Sales by Region (2017-2022) & (K Units)
    Table 79. Asia Pacific Human Vaccines Administered Orally Sales by Region (2023-2028) & (K Units)
    Table 80. Asia Pacific Human Vaccines Administered Orally Revenue by Region (2017-2022) & (US$ Million)
    Table 81. Asia Pacific Human Vaccines Administered Orally Revenue by Region (2023-2028) & (US$ Million)
    Table 82. Latin America Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
    Table 83. Latin America Human Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
    Table 84. Latin America Human Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
    Table 85. Latin America Human Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
    Table 86. Latin America Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
    Table 87. Latin America Human Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
    Table 88. Latin America Human Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
    Table 89. Latin America Human Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
    Table 90. Latin America Human Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
    Table 91. Latin America Human Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
    Table 92. Latin America Human Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
    Table 93. Latin America Human Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
    Table 94. Middle East and Africa Human Vaccines Administered Orally Sales by Type (2017-2022) & (K Units)
    Table 95. Middle East and Africa Human Vaccines Administered Orally Sales by Type (2023-2028) & (K Units)
    Table 96. Middle East and Africa Human Vaccines Administered Orally Revenue by Type (2017-2022) & (US$ Million)
    Table 97. Middle East and Africa Human Vaccines Administered Orally Revenue by Type (2023-2028) & (US$ Million)
    Table 98. Middle East and Africa Human Vaccines Administered Orally Sales by Application (2017-2022) & (K Units)
    Table 99. Middle East and Africa Human Vaccines Administered Orally Sales by Application (2023-2028) & (K Units)
    Table 100. Middle East and Africa Human Vaccines Administered Orally Revenue by Application (2017-2022) & (US$ Million)
    Table 101. Middle East and Africa Human Vaccines Administered Orally Revenue by Application (2023-2028) & (US$ Million)
    Table 102. Middle East and Africa Human Vaccines Administered Orally Sales by Country (2017-2022) & (K Units)
    Table 103. Middle East and Africa Human Vaccines Administered Orally Sales by Country (2023-2028) & (K Units)
    Table 104. Middle East and Africa Human Vaccines Administered Orally Revenue by Country (2017-2022) & (US$ Million)
    Table 105. Middle East and Africa Human Vaccines Administered Orally Revenue by Country (2023-2028) & (US$ Million)
    Table 106. Merck Corporation Information
    Table 107. Merck Description and Major Businesses
    Table 108. Merck Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 109. Merck Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 110. Merck Recent Developments
    Table 111. GSK Corporation Information
    Table 112. GSK Description and Major Businesses
    Table 113. GSK Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 114. GSK Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 115. GSK Recent Developments
    Table 116. Sanofi Corporation Information
    Table 117. Sanofi Description and Major Businesses
    Table 118. Sanofi Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 119. Sanofi Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 120. Sanofi Recent Developments
    Table 121. Lanzhou Institute Corporation Information
    Table 122. Lanzhou Institute Description and Major Businesses
    Table 123. Lanzhou Institute Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 124. Lanzhou Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 125. Lanzhou Institute Recent Developments
    Table 126. Serum Institute Corporation Information
    Table 127. Serum Institute Description and Major Businesses
    Table 128. Serum Institute Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 129. Serum Institute Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 130. Serum Institute Recent Developments
    Table 131. Valneva Corporation Information
    Table 132. Valneva Description and Major Businesses
    Table 133. Valneva Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 134. Valneva Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 135. Valneva Recent Developments
    Table 136. Shanghai United Cell Corporation Information
    Table 137. Shanghai United Cell Description and Major Businesses
    Table 138. Shanghai United Cell Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 139. Shanghai United Cell Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 140. Shanghai United Cell Recent Developments
    Table 141. Bibcol Corporation Information
    Table 142. Bibcol Description and Major Businesses
    Table 143. Bibcol Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 144. Bibcol Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 145. Bibcol Recent Developments
    Table 146. PaxVax Corporation Information
    Table 147. PaxVax Description and Major Businesses
    Table 148. PaxVax Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 149. PaxVax Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 150. PaxVax Recent Developments
    Table 151. Vabiotech Corporation Information
    Table 152. Vabiotech Description and Major Businesses
    Table 153. Vabiotech Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 154. Vabiotech Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 155. Vabiotech Recent Developments
    Table 156. Tiantan Biological Corporation Information
    Table 157. Tiantan Biological Description and Major Businesses
    Table 158. Tiantan Biological Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 159. Tiantan Biological Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 160. Tiantan Biological Recent Developments
    Table 161. EuBiologics Corporation Information
    Table 162. EuBiologics Description and Major Businesses
    Table 163. EuBiologics Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 164. EuBiologics Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 165. EuBiologics Recent Developments
    Table 166. Panacea Biotec Ltd Corporation Information
    Table 167. Panacea Biotec Ltd Description and Major Businesses
    Table 168. Panacea Biotec Ltd Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 169. Panacea Biotec Ltd Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 170. Panacea Biotec Ltd Recent Developments
    Table 171. Bio-Med Corporation Information
    Table 172. Bio-Med Description and Major Businesses
    Table 173. Bio-Med Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 174. Bio-Med Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 175. Bio-Med Recent Developments
    Table 176. Halfkin Bio-Pharmaceuticals Corporation Information
    Table 177. Halfkin Bio-Pharmaceuticals Description and Major Businesses
    Table 178. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 179. Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Model Numbers, Pictures, Descriptions and Specifications
    Table 180. Halfkin Bio-Pharmaceuticals Recent Developments
    Table 181. Key Raw Materials Lists
    Table 182. Raw Materials Key Suppliers Lists
    Table 183. Human Vaccines Administered Orally Distributors List
    Table 184. Human Vaccines Administered Orally Customers List
    Table 185. Human Vaccines Administered Orally Market Trends
    Table 186. Human Vaccines Administered Orally Market Drivers
    Table 187. Human Vaccines Administered Orally Market Challenges
    Table 188. Human Vaccines Administered Orally Market Restraints
    Table 189. Research Programs/Design for This Report
    Table 190. Key Data Information from Secondary Sources
    Table 191. Key Data Information from Primary Sources
List of Figures
    Figure 1. Human Vaccines Administered Orally Product Picture
    Figure 3. Global Human Vaccines Administered Orally Market Share by Type in 2021 & 2028
    Figure 3. Rotavirus Vaccine Product Picture
    Figure 4. Cholera Vaccine Product Picture
    Figure 5. Oral Polio Vaccine Product Picture
    Figure 6. Global Human Vaccines Administered Orally Market Share by Application in 2021 & 2028
    Figure 7. Public
    Figure 8. Private
    Figure 9. Human Vaccines Administered Orally Report Years Considered
    Figure 10. Global Human Vaccines Administered Orally Sales 2017-2028 (K Units)
    Figure 11. Global Human Vaccines Administered Orally Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Human Vaccines Administered Orally Revenue 2017-2028 (US$ Million)
    Figure 13. Global Human Vaccines Administered Orally Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 14. Global Human Vaccines Administered Orally Sales Market Share by Region (2017-2022)
    Figure 15. Global Human Vaccines Administered Orally Sales Market Share by Region (2023-2028)
    Figure 16. North America Human Vaccines Administered Orally Sales YoY (2017-2028) & (K Units)
    Figure 17. North America Human Vaccines Administered Orally Revenue YoY (2017-2028) & (US$ Million)
    Figure 18. Europe Human Vaccines Administered Orally Sales YoY (2017-2028) & (K Units)
    Figure 19. Europe Human Vaccines Administered Orally Revenue YoY (2017-2028) & (US$ Million)
    Figure 20. Asia-Pacific Human Vaccines Administered Orally Sales YoY (2017-2028) & (K Units)
    Figure 21. Asia-Pacific Human Vaccines Administered Orally Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Latin America Human Vaccines Administered Orally Sales YoY (2017-2028) & (K Units)
    Figure 23. Latin America Human Vaccines Administered Orally Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Middle East & Africa Human Vaccines Administered Orally Sales YoY (2017-2028) & (K Units)
    Figure 25. Middle East & Africa Human Vaccines Administered Orally Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. The Human Vaccines Administered Orally Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 27. The Top 5 and 10 Largest Manufacturers of Human Vaccines Administered Orally in the World: Market Share by Human Vaccines Administered Orally Revenue in 2021
    Figure 28. Global Human Vaccines Administered Orally Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 29. Global Human Vaccines Administered Orally Sales Market Share by Type (2017-2028)
    Figure 30. Global Human Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
    Figure 31. Global Human Vaccines Administered Orally Sales Market Share by Application (2017-2028)
    Figure 32. Global Human Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
    Figure 33. North America Human Vaccines Administered Orally Sales Market Share by Type (2017-2028)
    Figure 34. North America Human Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
    Figure 35. North America Human Vaccines Administered Orally Sales Market Share by Application (2017-2028)
    Figure 36. North America Human Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
    Figure 37. North America Human Vaccines Administered Orally Sales Share by Country (2017-2028)
    Figure 38. North America Human Vaccines Administered Orally Revenue Share by Country (2017-2028)
    Figure 39. U.S. Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 40. Canada Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 41. Europe Human Vaccines Administered Orally Sales Market Share by Type (2017-2028)
    Figure 42. Europe Human Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
    Figure 43. Europe Human Vaccines Administered Orally Sales Market Share by Application (2017-2028)
    Figure 44. Europe Human Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
    Figure 45. Europe Human Vaccines Administered Orally Sales Share by Country (2017-2028)
    Figure 46. Europe Human Vaccines Administered Orally Revenue Share by Country (2017-2028)
    Figure 47. Germany Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 48. France Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 49. U.K. Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 50. Italy Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 51. Russia Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 52. Asia Pacific Human Vaccines Administered Orally Sales Market Share by Type (2017-2028)
    Figure 53. Asia Pacific Human Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
    Figure 54. Asia Pacific Human Vaccines Administered Orally Sales Market Share by Application (2017-2028)
    Figure 55. Asia Pacific Human Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
    Figure 56. Asia Pacific Human Vaccines Administered Orally Sales Share by Region (2017-2028)
    Figure 57. Asia Pacific Human Vaccines Administered Orally Revenue Share by Region (2017-2028)
    Figure 58. China Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 59. Japan Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 60. South Korea Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 61. India Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 62. Australia Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 63. Taiwan Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 64. Indonesia Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 65. Thailand Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 66. Malaysia Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 67. Philippines Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 68. Latin America Human Vaccines Administered Orally Sales Market Share by Type (2017-2028)
    Figure 69. Latin America Human Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
    Figure 70. Latin America Human Vaccines Administered Orally Sales Market Share by Application (2017-2028)
    Figure 71. Latin America Human Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
    Figure 72. Latin America Human Vaccines Administered Orally Sales Share by Country (2017-2028)
    Figure 73. Latin America Human Vaccines Administered Orally Revenue Share by Country (2017-2028)
    Figure 74. Mexico Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 75. Brazil Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 76. Argentina Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 77. Middle East and Africa Human Vaccines Administered Orally Sales Market Share by Type (2017-2028)
    Figure 78. Middle East and Africa Human Vaccines Administered Orally Revenue Market Share by Type (2017-2028)
    Figure 79. Middle East and Africa Human Vaccines Administered Orally Sales Market Share by Application (2017-2028)
    Figure 80. Middle East and Africa Human Vaccines Administered Orally Revenue Market Share by Application (2017-2028)
    Figure 81. Middle East and Africa Human Vaccines Administered Orally Sales Share by Country (2017-2028)
    Figure 82. Middle East and Africa Human Vaccines Administered Orally Revenue Share by Country (2017-2028)
    Figure 83. Turkey Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 84. Saudi Arabia Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 85. U.A.E Human Vaccines Administered Orally Revenue (2017-2028) & (US$ Million)
    Figure 86. Human Vaccines Administered Orally Value Chain
    Figure 87. Human Vaccines Administered Orally Production Process
    Figure 88. Channels of Distribution
    Figure 89. Distributors Profiles
    Figure 90. Bottom-up and Top-down Approaches for This Report
    Figure 91. Data Triangulation
    Figure 92. Key Executives Interviewed